Internal Medicine, Hematology & Oncology · Knoxville, TN
NPI
1003804204
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1415 Old Weisgarber Rd, Suite 200
Knoxville, TN, 37909
Phone (865) 934-5800
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.7M
129,222 services
Medicare patients, 2024
489
Average age 74
Drug cost, 2024
$5.4M
535 prescriptions
Company payments, 2025
$1,544
From 31 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Saji Eapen was code J0185 (injection, aprepitant, 1 mg), 11,310 times for 11 patients. In total Saji Eapen billed 129,222 services in 134 codes, and Medicare paid $2.7M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-09-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0185 Injection, aprepitant, 1 mg | Office | 11,310 | 11 | $1.34 | $15K |
| J0897 Injection, denosumab, 1 mg | Office | 9,180 | 40 | $20.50 | $188K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 4,500 | 28 | $15.80 | $71K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,620 | 21 | $0.09 | $146 |
| 85025 Blood Count | Office | 1,102 | 316 | $7.60 | $8,374 |
| 36415 Venipuncture Blood Collection | Office | 964 | 334 | $8.62 | $8,306 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 952 | 15 | $0.07 | $69.26 |
| 80053 Clinical Chemistry | Office | 916 | 316 | $10.32 | $9,454 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 490 | 12 | $0.77 | $378 |
| 99214 Office E&M - Established | Office | 475 | 207 | $87.69 | $42K |
| 99213 Office E&M - Established | Office | 389 | 254 | $58.33 | $23K |
| 96372 Injection Administration | Office | 346 | 71 | $10.18 | $3,521 |
| 96413 Chemotherapy Administration | Office | 277 | 35 | $89.32 | $25K |
| 82728 Clinical Chemistry | Office | 252 | 127 | $13.36 | $3,367 |
| 82784 Immunoassay | Office | 249 | 31 | $9.11 | $2,269 |
By year: 2022 $2.9M for 180,438 services; 2023 $2.7M for 124,184 services; 2024 $2.7M for 129,222 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,102 | 316 | $7.60 | $8,374 |
| 36415 Venipuncture Blood Collection | 964 | 334 | $8.62 | $8,306 |
| 80053 Clinical Chemistry | 916 | 316 | $10.32 | $9,454 |
| 82728 Clinical Chemistry | 252 | 127 | $13.36 | $3,367 |
| 82784 Immunoassay | 249 | 31 | $9.11 | $2,269 |
| 83540 Clinical Chemistry | 240 | 127 | $6.34 | $1,522 |
| 83550 Clinical Chemistry | 230 | 120 | $8.57 | $1,971 |
| 83521 Immunoassay | 142 | 26 | $16.93 | $2,403 |
| 83615 Clinical Chemistry | 97 | 76 | $5.92 | $574 |
| 82607 Clinical Chemistry | 77 | 64 | $14.78 | $1,138 |
Medicare prescription drug claims, 2024
In 2024, the drug Saji Eapen prescribed most often to Medicare patients was Imbruvica (Ibrutinib), with 44 prescriptions and refills. In total Saji Eapen wrote 535 Medicare prescriptions that cost $5.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Imbruvica Ibrutinib | 44 | 44 | Under 11 | $708K |
| Revlimid Lenalidomide | 41 | 41 | Under 11 | $635K |
| Ondansetron Hcl Generic | 40 | 40 | 24 | $280 |
| Calquence Acalabrutinib Maleate | 30 | 30 | Under 11 | $458K |
| Ibrance Palbociclib | 24 | 24 | Under 11 | $360K |
| Lenalidomide Generic | 21 | 21 | Under 11 | $280K |
| Levofloxacin Generic | 20 | 20 | Under 11 | $56.02 |
| Prednisone Generic | 19 | 19 | Under 11 | $103 |
| Hydroxyurea Generic | 16 | 36 | Under 11 | $422 |
| Brukinsa Zanubrutinib | 16 | 16 | Under 11 | $201K |
| Dexamethasone Generic | 15 | 17 | 11 | $309 |
| Anastrozole Generic | 14 | 40 | Under 11 | $208 |
| Venclexta Venetoclax | 14 | 14 | Under 11 | $199K |
| Xtandi Enzalutamide | 14 | 14 | Under 11 | $188K |
| Scemblix Asciminib Hydrochloride | 12 | 12 | Under 11 | $1.3M |
Brand drugs: 283 claims; generic drugs: 252 claims; opioid claims: 22.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Saji Eapen $1,544 ($1,544 in general payments such as food, travel and fees) from 31 companies. The largest payer was Abbvie Inc. with $150.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 7 | $150 |
| Iovance Biotherapeutics, Inc. IOVA | 2 | $145 |
| Novartis Pharmaceuticals Corporation NVS | 6 | $127 |
| Pfizer Inc. PFE | 5 | $112 |
| Gilead Sciences, Inc. GILD | 5 | $108 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $92.6 |
| Jazz Pharmaceuticals Inc. JAZZ | 1 | $89.99 |
| Celgene Corporation BMY | 3 | $64.28 |
| Regeneron Healthcare Solutions, Inc. REGN | 3 | $60.72 |
| Daiichi Sankyo Inc. 4568.T | 2 | $48.46 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.